Research programme: antipsychotic therapeutics - Assertio Therapeutics
Alternative Names: NEO 376; NEO 392; SPI 376; SPI 392Latest Information Update: 22 Jun 2026
At a glance
- Originator Spectrum Pharmaceuticals
- Developer Assertio Therapeutics
- Class
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D4 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Psychotic disorders